Stockscreener 앱 받기
1.67
4.57%
-0.08
시간 외 거래:
1.69
0.02
+1.20%
전일 마감가:
$1.75
열려 있는:
$1.75
하루 거래량:
245.82K
Relative Volume:
0.32
시가총액:
$71.48M
수익:
-
순이익/손실:
$-77.27M
주가수익비율:
-0.8342
EPS:
-2.0019
순현금흐름:
$-66.29M
1주 성능:
+4.37%
1개월 성능:
-12.57%
6개월 성능:
-29.24%
1년 성능:
+42.74%
1일 변동 폭
$1.67
$1.795
1주일 범위
$1.62
$1.90
52주 변동 폭
$1.05
$3.56
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
명칭
Acrivon Therapeutics Inc
전화
617-207-8979
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.67 | 74.90M | 0 | -77.27M | -66.29M | -2.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-05 | 재개 | Piper Sandler | Overweight |
| 2025-01-31 | 개시 | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-12-15 | 재개 | Jefferies | Buy |
| 2023-10-05 | 개시 | Maxim Group | Buy |
| 2023-06-02 | 개시 | Oppenheimer | Outperform |
| 2023-05-08 | 개시 | BMO Capital Markets | Outperform |
| 2023-04-27 | 개시 | Ladenburg Thalmann | Buy |
| 2023-04-20 | 개시 | H.C. Wainwright | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-12-12 | 개시 | Jefferies | Buy |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
모두보기
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Acrivon (ACRV) CEO and EVP report RSU-related tax withholding move - Stock Titan
ACRV Stock Price, Quote & Chart | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline By Investing.com - Investing.com Australia
Acrivon Therapeutics CEO to Participate in Virtual Fireside Chat at TD Cowen’s 7th Annual Oncology Innovation Summit - Quiver Quantitative
Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit - The Manila Times
Acrivon CEO to join TD Cowen cancer innovation webcast May 26 - Stock Titan
9,366 RSUs granted to Acrivon (ACRV) director for RA Capital funds - Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units as equity award - Stock Titan
Director at Acrivon Therapeutics (ACRV) awarded 9,366 RSUs vesting 2027 - Stock Titan
Acrivon Therapeutics (ACRV) director receives 9,366 RSUs vesting in 2027 - Stock Titan
Acrivon (ACRV) director receives 9,366 restricted stock units in equity grant - Stock Titan
Acrivon Therapeutics (ACRV) CFO awarded 46,167 RSUs, holdings rise to 67,150 shares - Stock Titan
Acrivon Therapeutics (ACRV) director receives 9,366 RSUs award - Stock Titan
Acrivon Therapeutics (ACRV) director granted 9,366 restricted stock units - Stock Titan
Acrivon Therapeutics (ACRV) CAO awarded 14,227 RSUs in equity grant - Stock Titan
Acrivon Therapeutics (ACRV) CMO receives 38,817-share restricted stock unit grant - Stock Titan
Acrivon Therapeutics (ACRV) grants 49,830 RSUs to Chief Legal Officer Mary Miller - Stock Titan
Acrivon Therapeutics (ACRV) CDO receives 38,584-share RSU grant with staged vesting - Stock Titan
Acrivon (ACRV) COO Eric Devroe receives 72,981 RSU stock grant - Stock Titan
Acrivon Therapeutics (ACRV) leaders receive new RSU and stock grants - Stock Titan
ACRV News | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill
Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock - simplywall.st
Acrivon (NASDAQ: ACRV) CLO has 184 shares withheld for RSU tax - Stock Titan
Acrivon Therapeutics (ACRV) CAO reports 99-share tax withholding on RSU vesting - Stock Titan
Acrivon (ACRV) CDO has 404 shares withheld to cover RSU tax liability - Stock Titan
[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity - Stock Titan
Acrivon (NASDAQ: ACRV) leaders use 1,743 shares for RSU tax withholding - Stock Titan
Maxim Group Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy - TipRanks
Number of shareholders of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Citadel affiliates disclose 13‑share stake in Acrivon (NASDAQ: ACRV) - Stock Titan
Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer - The Globe and Mail
Citizens reiterates Acrivon Therapeutics stock rating on cancer trial progress By Investing.com - Investing.com Australia
Citizens reiterates Acrivon Therapeutics stock rating on cancer trial progress - Investing.com
H.C. Wainwright Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials - TipRanks
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts - Sahm
Key facts: ACRV ACR-368 ORR 39%; PD-1 combo P3 planned; Q1 loss $19M - TradingView
Acrivon Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Acrivon Therapeutics Q1 Loss Narrows - Moomoo
Acrivon Therapeutics Q1 net loss narrows - TradingView
Biotech Acrivon has cash to advance cancer drugs into Q3 2027 - Stock Titan
Acrivon Therapeutics (NASDAQ: ACRV) posts Q1 loss and extends cash runway - Stock Titan
Acrivon (Nasdaq: ACRV) posts Q1 2026 loss and extends cash runway - Stock Titan
The strategic moves Acrivon (ACRV) is making now (-1.26%) 2026-05-11Bullish Pattern - newser.com
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MSN Money - MSN
Acrivon Therapeutics Inc (ACRV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):